OPEN END-TURBO-OPTIONSSCHEIN - INCYTE CO. | Real-time BOERSE MUENCHEN 12:36:51 03/07/2024 BST | ||
| 1.21 EUR | 0.00% |
|
| Current month | -8.33% | ||
| 1 month | +11.01% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
INCYTE CORPORATION
Latest news about INCYTE CORPORATION
| Date | Price | Change |
|---|---|---|
| 03/07/24 | 1.21 | 0.00% |
| 02/07/24 | 1.21 | -12.95% |
| 01/07/24 | 1.39 | +5.30% |
| 28/06/24 | 1.32 | -7.69% |
| 27/06/24 | 1.43 | -3.38% |
Real-time BOERSE MUENCHEN
Last update July 03, 2024 at 12:36 pm
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | INCYTE CORPORATION |
| Issuer | HSBC |
| WKN | HG9LGD |
| ISIN | DE000HG9LGD3 |
| Date issued | 12/05/2023 |
| Strike | 46.38 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.15 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.34 € |
|---|---|
| Lowest since issue | 0.52 € |
| Spread | 0.05 € |
| Spread % | 4.00% |
Company Profile
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows:
- product sales (85.6%);
- royalties (14.2%);
- income from research and cooperation agreements (0.2%).
Sector
-
Consensus: Incyte Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
59.02
USD
Average target price
72.62
USD
Spread / Average Target
+23.04%
- Stock Market
- Certificates
- Certificat
